Croatia is a compact EU clinical trial market with strong regional value.
With a population of 3.9 million, full CTIS integration and the highest number of clinical trials per capita in the Balkans, Croatia gives sponsors a credible European pathway into Southeast European research.
Its trial activity is especially relevant across oncology, mental health, endocrinology, cardiovascular disease, rare diseases and medical devices.
For sponsors, Croatia is useful because it combines EU regulatory standards with Central and Eastern European cost levels, motivated investigators and a strong university hospital network anchored by Zagreb.